Alnylam Pharmaceuticals $ALNY

Health Care · Biotechnology · NASDAQ

$143.82
-4.00 (-2.71%)
As of Nov 20, 2026, 4:05 PM EST
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 23, 2026, the first target we tracked for ALNY.

Key facts

Market cap
$19.26B $143.82 as of Nov 20, 2026, 4:05 PM EST × 133.94M shares outstanding as of Oct 23, 2026, from the 10-Q cover page (SEC filings)
P/E (trailing)
7.5 $143.82 as of Nov 20, 2026, 4:05 PM EST ÷ diluted EPS of $19.25 for the four quarters to Sep 30, 2026, one of them a fourth quarter derived as the fiscal year less the first three
EPS (trailing 12 months)
$19.25 Diluted, the four quarters to Sep 30, 2026, one of them a fourth quarter derived as the fiscal year less the first three, summed, from SEC filings
52-week range (closes)
$143.82 – $473.29 Lowest close Nov 20, 2026, highest Dec 3, 2025; 251 daily closes to Nov 20, 2026 from Dalsna Finance's price archive
Fiscal year ends
December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the Nasdaq-100 since
Dec 22, 2025, replacing Biogen (BIIB), CDW Corporation (CDW), GlobalFoundries (GFS), Lululemon Athletica (LULU), ON Semiconductor (ON) and Trade Desk (The) (TTD) · Annual index reconstitution. · All Nasdaq-100 changes
Analyst coverage
9 open price targets from 8 firms: Raymond James, Bernstein, Canaccord Genuity, Freedom Broker, Needham, RBC Capital Markets, Stifel, Truist Securities Approved targets tracked here; see the analyst section below

Alnylam Pharmaceuticals (ALNY) is trading down at $143.82 (-2.71%) on NASDAQ, as of the latest quote. It is a Nasdaq-100 constituent in the Health Care sector.

Analyst price targets on ALNY

What the tracked firms say

9 open price targets on Alnylam Pharmaceuticals from 8 firms, as of Nov 2, 2026 (the newest target counted).

4 Buy or equivalent1 Hold or equivalent0 Sell or equivalent

3 firms stated no rating.

Average target
$270
Median
$262
High
$350
Low
$199
Firms counted
8

Counted from the targets listed below: each firm once, at its latest open target. Ratings are the firms' own words, grouped only where the word is unambiguous. This is a summary of what the firms published, not a forecast or advice from Dalsna Finance, and it is not a consensus estimate. How we collect and score targets.

9 targets, newest first. Open a row for its source and scoring.

DateNov 2, 2026 FirmTruist Securities Ratinglowers Targetat $161 · $225 +40% Horizonby Nov 2027 StatusOpen

Entry price $161, the close nearest Nov 2, 2026, when the target was reported; the target is +40% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 2, 2027.

Source ALNY Downgraded by Truist Securities -- Price Target Lowered to $225 GuruFocus · Nov 2, 2026 · opens the publisher's site
ALNY Downgraded by Truist Securities -- Price Target Lowered to $225
DateNov 2, 2026 FirmCanaccord Genuity RatingBuy · lowers Targetat $158 · $323 +104% Horizonby Nov 2027 StatusOpen

Entry price $158, the close nearest Nov 2, 2026, when the target was reported; the target is +104% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 2, 2027.

Source ALNY Maintained by Canaccord Genuity -- Price Target Lowered to $323 GuruFocus · Nov 2, 2026 · opens the publisher's site
ALNY Maintained by Canaccord Genuity -- Price Target Lowered to $323
DateOct 30, 2026 FirmBernstein Ratinglowers Targetat $165 · $199 +21% Horizonby Oct 2027 StatusOpen

Entry price $165, the close nearest Oct 30, 2026, when the target was reported; the target is +21% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 30, 2027.

Source ALNY Downgraded by Bernstein -- Price Target Lowered to $199 GuruFocus · Oct 30, 2026 · opens the publisher's site
ALNY Downgraded by Bernstein -- Price Target Lowered to $199
DateOct 30, 2026 FirmFreedom Broker RatingBuy · lowers Targetat $174 · $350 +101% Horizonby Oct 2027 StatusOpen

Entry price $174, the close nearest Oct 30, 2026, when the target was reported; the target is +101% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 30, 2027.

Source Freedom Broker cuts Alnylam stock price target on execution risks Investing.com · Oct 30, 2026 · opens the publisher's site
Freedom Broker lowered its price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) to $350 from $410
DateOct 30, 2026 FirmRBC Capital Markets Ratinglowers Targetat $165 · $280 +70% Horizonby Oct 2027 StatusOpen

Entry price $165, the close nearest Oct 30, 2026, when the target was reported; the target is +70% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 30, 2027.

Source ALNY Maintained by RBC Capital -- Price Target Lowered to $280 GuruFocus · Oct 30, 2026 · opens the publisher's site
ALNY Maintained by RBC Capital -- Price Target Lowered to $280
DateOct 30, 2026 FirmRaymond James RatingOutperform · lowers Targetat $165 · $315 +91% Horizonby Oct 2027 StatusOpen

Entry price $165, the close nearest Oct 30, 2026, when the target was reported; the target is +91% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 30, 2027.

Source ALNY Downgraded by Raymond James -- Price Target Lowered to $315 GuruFocus · Oct 30, 2026 · opens the publisher's site
ALNY Downgraded by Raymond James -- Price Target Lowered to $315
DateOct 29, 2026 FirmNeedham RatingBuy · lowers Targetat $174 · $243 +40% Horizonby Oct 2027 StatusOpen

Entry price $174, the close nearest Oct 29, 2026, when the target was reported; the target is +40% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 29, 2027.

Source ALNY Maintained by Needham -- Price Target Lowered to $243 GuruFocus · Oct 29, 2026 · opens the publisher's site
Needham cut its target price for Alnylam Pharmaceuticals to $243 from $357.
DateOct 29, 2026 FirmStifel RatingHold · lowers Targetat $174 · $225 +29% Horizonby Oct 2027 StatusOpen

Entry price $174, the close nearest Oct 29, 2026, when the target was reported; the target is +29% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 29, 2027.

Source Stifel Downgrades Alnylam Pharmaceuticals (ALNY) to Hold StreetInsider · Oct 29, 2026 · opens the publisher's site
Stifel downgraded Alnylam (ALNY) to Hold from Buy with a price target of $225, down from $318
DateOct 23, 2026 FirmRaymond James RatingStrong Buy · reiterates Targetat $224 · $420 +87% Horizonby Oct 2027 StatusOpen

Entry price $224, the close nearest Oct 23, 2026, when the target was reported; the target is +87% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 23, 2027.

Source Raymond James reiterates Alnylam stock Strong Buy on positive trial data Investing.com · Oct 23, 2026 · opens the publisher's site
Raymond James reiterated a Strong Buy rating and $420.00 price target on Alnylam Pharmaceuticals

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Analysts covering Alnylam Pharmaceuticals

8 firms have a price target on Alnylam Pharmaceuticals tracked here, newest first. Each links to that firm's full record.

Alnylam Pharmaceuticals revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$3.71B$1.29B−$1.13BFY2016 revenue: $47.2MFY2016 net income: −$410.1M · Net margin −869.6%'16FY2017 revenue: $89.9MFY2017 net income: −$490.9M · Net margin −545.9%'17FY2018 revenue: $74.9MFY2018 net income: −$761.5M · Net margin −1016.6%'18FY2019 revenue: $219.8MFY2019 net income: −$886.1M · Net margin −403.2%'19FY2020 revenue: $492.9MFY2020 net income: −$858.3M · Net margin −174.1%'20FY2021 revenue: $844.3MFY2021 net income: −$852.8M · Net margin −101.0%'21FY2022 revenue: $1.04BFY2022 net income: −$1.13B · Net margin −109.0%'22FY2023 revenue: $1.83BFY2023 net income: −$440.2M · Net margin −24.1%'23FY2024 revenue: $2.25BFY2024 net income: −$278.2M · Net margin −12.4%'24FY2025 revenue: $3.71BFY2025 net income: $313.7M · Net margin 8.4%'25−6.1%0%10%20%FY2016 net margin: −869.6% (off the scale, which stops at −6.1%)FY2017 net margin: −545.9% (off the scale, which stops at −6.1%)FY2018 net margin: −1016.6% (off the scale, which stops at −6.1%)FY2019 net margin: −403.2% (off the scale, which stops at −6.1%)FY2020 net margin: −174.1% (off the scale, which stops at −6.1%)FY2021 net margin: −101.0% (off the scale, which stops at −6.1%)FY2022 net margin: −109.0% (off the scale, which stops at −6.1%)FY2023 net margin: −24.1% (off the scale, which stops at −6.1%)FY2024 net margin: −12.4% (off the scale, which stops at −6.1%)FY2025 net margin: 8.4%
Alnylam Pharmaceuticals annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$47.2M$89.9M$74.9M$219.8M$492.9M$844.3M$1.04B$1.83B$2.25B$3.71B
Growth (year over year)—+90.7%−16.7%+193.4%+124.3%+71.3%+22.9%+76.2%+23.0%+65.2%
Gross profit—$89.9M$73.1M$194.7M$418.7M$729.3M$897.2M$1.56B$1.94B$3.04B
Gross margin—100.0%97.6%88.6%84.9%86.4%86.5%85.3%86.4%81.8%
Operating income−$424.6M−$500.1M−$814.7M−$939.4M−$828.4M−$708.7M−$785.1M−$282.2M−$176.9M$501.6M
Operating margin−900.3%−556.2%−1087.6%−427.5%−168.1%−83.9%−75.7%−15.4%−7.9%13.5%
Net income−$410.1M−$490.9M−$761.5M−$886.1M−$858.3M−$852.8M−$1.13B−$440.2M−$278.2M$313.7M
Net margin−869.6%−545.9%−1016.6%−403.2%−174.1%−101.0%−109.0%−24.1%−12.4%8.4%
EPS (diluted)−$4.79−$5.42−$7.57−$8.11−$7.46−$7.20−$9.30−$3.52−$2.18$2.33
Balance sheet
Cash and equivalents$193.6M$645.4M$420.1M$547.2M$496.6M$820.0M$866.4M$812.7M$966.4M$1.66B
Total assets$1.26B$1.99B$1.57B$2.40B$3.41B$3.64B$3.55B$3.83B$4.24B$4.97B
Total liabilities$342.6M$228.3M$272.8M$956.4M$2.39B$3.06B$3.70B$4.05B$4.17B$4.18B
Long-term debt————$191.3M$675.7M————
Shareholders' equity$920.2M$1.77B$1.30B$1.44B$1.02B$588.2M−$158.2M−$220.6M$67.1M$789.2M
Cash flow
Operating cash flow−$307.7M−$382.8M−$562.6M−$278.4M−$615.0M−$641.7M−$541.3M$104.2M−$8.31M$524.1M
Capital expenditure$64.6M$104.2M$126.9M$140.2M$70.4M$76.4M$72.1M$62.2M$34.3M$58.7M
Free cash flow−$372.3M−$487.0M−$689.5M−$418.6M−$685.3M−$718.1M−$613.3M$41.9M−$42.6M$465.4M

From Alnylam Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Alnylam Pharmaceuticals earnings by quarter

The last 8 quarters as Alnylam Pharmaceuticals (ALNY) reported them to the SEC: revenue and diluted earnings per share under GAAP, as filed (a figure marked * is our calculation, not a filed one). No estimates. The change columns are our calculation from these figures.

Fiscal quarter Reported Revenue vs prior quarter (our calculation) vs a year earlier (our calculation) Diluted EPS vs prior quarter (our calculation) vs a year earlier (our calculation) Filings
Q3 FY2026Jul–Sep 2026 Oct 29, 2026 $1.46B +12.9% +16.7% $15.72 +1199.2% +634.6%
Q2 FY2026Apr–Jun 2026 Jul 30, 2026 $1.29B +10.6% +66.9% $1.21 n/a n/a
Q1 FY2026Jan–Mar 2026 Apr 30, 2026 $1.17B* +6.4% +96.4% —† n/a n/a
Q4 FY2025Oct–Dec 2025 Feb 12, 2026 $1.10B* −12.2% +84.9% —† n/a n/a
Q3 FY2025Jul–Sep 2025 Oct 30, 2025 $1.25B +61.4% +149.3% $2.14 n/a n/a
Q2 FY2025Apr–Jun 2025 Jul 31, 2025 $773.7M +30.2% +17.3% −$0.55 n/a n/a
Q1 FY2025Jan–Mar 2025 May 1, 2025 (10-Q filed) $594.2M +0.2% +20.2% −$0.14 n/a n/a
Q4 FY2024Oct–Dec 2024 Jan 13, 2025 $593.2M* +18.4% +34.9% —† n/a n/a

"Reported" is the day the results release (an 8-K under Item 2.02) was accepted by the SEC; where we have none on file it is the day the quarterly or annual report was filed, and says which. * Our calculation: revenue for a fourth quarter the company reports only within its full year, worked out as the 10-K's year less the first three quarters. † Not shown: the company reports this quarter's diluted EPS only within its full year, and per-share amounts do not add up across quarters (the share count changes), so the year less nine months would differ from the company's own fourth-quarter figure. Changes against it are left blank too. n/a: no comparable quarter, or a zero or negative base, where a percentage would mislead. Source: the company's filings on SEC EDGAR.

Alnylam Pharmaceuticals in the news

Nov 21, 2026 Simply Wall St Alnylam Pharmaceuticals (ALNY) Wins FDA Approval in Myasthenia Gravis With Seventh RNAi Drug
Nov 19, 2026 Kalkine Media Is Alnylam (NASDAQ:ALNY) Proving Its RNAi Platform With Another Approval?
Nov 19, 2026 Stock Traders Daily Why (ALNY) Price Action Is Critical for Tactical Trading
Nov 19, 2026 Yahoo Finance Alnylam Pharmaceuticals (ALNY) Stock Dropped, So What Is Driving Attention Now?
Nov 19, 2026 Stock Titan Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years
Show 5 older stories
Nov 17, 2026 Trefis Alnylam Stock Trades Below Its Pre-$1 Billion Buyback Price
Nov 16, 2026 Simply Wall St Did Alnylam Pharmaceuticals' 64% Drop Catch You Out? What Bears Saw
Nov 16, 2026 Yahoo Finance What Is Driving Alnylam Stock?
Nov 12, 2026 Yahoo Finance What Moved Alnylam Stock?
Nov 2, 2026 Yahoo Finance Should You Buy The Dip In Alnylam Stock?

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Source: Wikipedia — Alnylam Pharmaceuticals

Headquarters
Cambridge, Massachusetts From SEC filings, Oct 2026

Reader scorecards on ALNY

No public reader scorecards on Alnylam Pharmaceuticals yet. Set a price target with a date and it is scored in public.

Make your own scorecard

More Health Care stocks

Browse all companies →

How federal capital gains are taxed (general information, not tax advice)